NAYA Biosciences Inc
NASDAQ:NAYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NAYA Biosciences Inc
Net Issuance of Debt
NAYA Biosciences Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
Net Issuance of Debt
-$229.4k
|
CAGR 3-Years
21%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Issuance of Debt
-$491m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Net Issuance of Debt
$1.6B
|
CAGR 3-Years
50%
|
CAGR 5-Years
10%
|
CAGR 10-Years
42%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Issuance of Debt
-$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-83%
|
CAGR 10-Years
-14%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
What is NAYA Biosciences Inc's Net Issuance of Debt?
Net Issuance of Debt
-229.4k
USD
Based on the financial report for Sep 30, 2024, NAYA Biosciences Inc's Net Issuance of Debt amounts to -229.4k USD.
What is NAYA Biosciences Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
2%
The average annual Net Issuance of Debt growth rates for NAYA Biosciences Inc have been 21% over the past three years , 2% over the past five years .
